Lymphoma, Non-Hodgkin Clinical Trials

23 recruiting

Lymphoma, Non-Hodgkin Trials at a Glance

27 actively recruiting trials for lymphoma, non-hodgkin are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in New York, Seattle, and Philadelphia. Lead sponsors running lymphoma, non-hodgkin studies include Janssen Research & Development, LLC, National Cancer Institute (NCI), and Assistance Publique - Hôpitaux de Paris.

Browse lymphoma, non-hodgkin trials by phase

Treatments under study

About Lymphoma, Non-Hodgkin Clinical Trials

Looking for clinical trials for Lymphoma, Non-Hodgkin? There are currently 23 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lymphoma, Non-Hodgkin trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lymphoma, Non-Hodgkin clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Multiple MyelomaLymphoma, Non-HodgkinLeukemia-Lymphoma, Adult T-Cell+1 more
National Cancer Institute (NCI)500 enrolled1 locationNCT02682667
Recruiting

Tissue Collection for Studies of Lymph Cancer

Multiple MyelomaLymphoma, Non-HodgkinLeukemia-Lymphoma, Adult T-Cell+2 more
National Cancer Institute (NCI)1,295 enrolled2 locationsNCT01676805
Recruiting

AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients.

Lymphoma, Non-HodgkinCare Coordination
Grand Hôpital de Charleroi210 enrolled1 locationNCT07546188
Recruiting
Phase 1Phase 2

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Lymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC439 enrolled32 locationsNCT05421663
Recruiting
Phase 1

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies

Lymphoma, Non-Hodgkin
Janssen Research & Development, LLC130 enrolled8 locationsNCT07308132
Recruiting
Not Applicable

Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

LymphomaSedentary BehaviorLymphoma, Non-Hodgkin+1 more
Dana-Farber Cancer Institute24 enrolled1 locationNCT06923397
Recruiting
Phase 2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
American Society of Clinical Oncology4,200 enrolled174 locationsNCT02693535
Recruiting
Phase 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
Canadian Cancer Trials Group720 enrolled10 locationsNCT03297606
Recruiting
Phase 2

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Lymphoma, Non-HodgkinB-cell LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Eli Lilly and Company13 enrolled6 locationsNCT07162181
Recruiting
Phase 1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Lymphoma, B-CellChronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)+1 more
Umoja Biopharma106 enrolled8 locationsNCT06528301
Recruiting

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

Lymphoma, Non-HodgkinHodgkin's Disease
Stanford University9,999 enrolled1 locationNCT00398177
Recruiting

Family Study of Lymphoproliferative Disorders

Multiple MyelomaLymphoma, Non-HodgkinLymphoma, B-Cell+2 more
Mayo Clinic3,000 enrolled1 locationNCT00626496
Recruiting
Not Applicable

Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients

Lymphoma, Non-Hodgkin
Assistance Publique - Hôpitaux de Paris30 enrolled1 locationNCT06133426
Recruiting
Phase 1

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin
Dizal Pharmaceuticals230 enrolled5 locationsNCT05824585
Recruiting
Phase 1Phase 2

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin LymphomaNon-Hodgkin's LymphomaLymphomas Non-Hodgkin's B-Cell+2 more
Estrella Biopharma, Inc.21 enrolled2 locationsNCT06343311
Recruiting
Phase 1Phase 2

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Lymphoma, Non-HodgkinLymphoma, B-CellLarge B-cell Lymphoma+3 more
Cancer Research UK84 enrolled7 locationsNCT06045910
Recruiting
Phase 4

Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma

Lymphoma, Non-HodgkinStreptococcus PneumoniaeVaccine
Poitiers University Hospital160 enrolled7 locationsNCT04460235
Recruiting
Phase 2

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myeloid Leukemia+4 more
University of Florida20 enrolled1 locationNCT05800210
Recruiting

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

Lymphoma, Non-HodgkinLymphoma, Hodgkin
Samsung Medical Center600 enrolled1 locationNCT03117036
Recruiting
Phase 1

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Diffuse Large B Cell LymphomaLymphoma, Non-HodgkinFollicular Lymphoma
Weill Medical College of Cornell University38 enrolled1 locationNCT05618366